Moderna maintains a high efficacy rate for its COVID-19 vaccine
In a significant development in the global fight against COVID-19, American biotechnology company Moderna has announced an efficacy rate of 94.5% for its vaccine candidate. This promising figure places Moderna's vaccine ahead of the pack, with initial reports suggesting it may be more effective than the vaccine developed by German biotechnology company BioNTech and U.S. pharmaceutical giant Pfizer, which has an efficacy rate over 90%.
Moderna's Phase-3 study, which involved over 30,000 participants in the U.S., recorded a total of 95 COVID-19 infections. A staggering 90 of these cases were found in the placebo group, while only five infections were recorded among vaccine recipients. Moreover, all 11 severe COVID-19 symptoms were found exclusively in the placebo group.
The rapid progress of Moderna's vaccine is indeed impressive. The company had already announced the development of a COVID-19 vaccine in January, and began its Phase-3 study in late July. In March, Moderna became the first company worldwide to receive approval for a clinical study for a SARS-CoV-2 vaccine. Remarkably, Moderna's Phase-3 study skipped the usual animal experimental studies.
The success of Moderna's vaccine is a beacon of hope in these challenging times. The vaccine, if approved, could play a crucial role in controlling the spread of the virus and returning life to some semblance of normality.
As the world eagerly awaits the rollout of effective vaccines, the race to immunise the global population against COVID-19 continues. With Moderna's promising vaccine, there is renewed optimism that we are one step closer to defeating this pandemic.
Photo credit: dts News Agency
Read also:
- High recovery rate for over 90% of patients, asserts the head physician of Almaty's 32nd polyclinic, regarding mobile treatment groups.
- Bee colonies in Zirndorf city have been affected by American foulbrood - a designated restriction zone has been established - no immediate threat to local residents.
- Federal Health Care Blueprint for 2026 Revealed by OPM Outlining Key Strategies and Objectives
- Unveiling the Undiscussed Issues of Earbuds: Revealing the Silent Reality
